Principal Advisors

Frederick Frank, Vice Chairman and a Director of Lehman Brothers Inc.

Frederick Frank has over 50 years of experienced in investment banking services to companies in the pharmaceutical, biotechnology, healthcare service providers, medical device and nutraceutical industries, and has been involved in hundreds of financings and merger and acquisition transactions in the health care field. Before joining Lehman Brothers as a Partner in October, 1969, Mr. Frank was co-director of research, as well as Vice President and Director, of Smith, Barney & Co. Inc. He is a Chartered Financial Analyst, a member of The New York Society of Security Analysts and a past president of the Chemical Processing Industry Analysts. In addition to serving as the Chairman of the Board of Predix Pharmaceuticals, Mr. Frank is a Director of Diagnostic Products Corporation, Digital Arts & Sciences, Inc., eSoft, Inc., Landec Corporation, Institute for Systems Biology, ICON Biopharma, Inc., and Pharmaceutical Product Development, Inc. He is Chairman of the National Genetics Foundation, a past director of the Salk Institute, a member of the Yale School of Management Advisory Board, a member of the Pharmaceutical Executive Magazine advisory board, Chairman of the Board of The Irvington Institute for Immunological Research, a member of the Advisory Board of The Harvard School of Public Health and also the John's Hopkin's Bloomberg School of Public Health, and he serves on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation.

Geoffrey Barker, M.D., Executive-in-Residence, A. M. Pappas & Associates and Former Chief Medical and Scientific Officer, Quintiles Transnational

Geoffrey Barker has held senior executive, medical, scientific and clinical positions with Astra, Actelion Pharmaceuticals, and Quintiles Transnational, for which he most recently served as Chief Medical and Scientific Officer. He was a member of Actelion's senior management team when it completed its successful IPO. Dr. Barker is a UK-qualified physician and is a Fellow of the Royal College of Physicians, a Fellow of the Royal Colleges of Surgeons, and a Fellow of the Royal College of Dental Surgeons. He is currently an Adjunct Professor in Immunology at Duke University Medical School and Executive-in-Residence, A. M. Pappas & Associates

James G. Shook, Ph.D. , President, Jim Shook Research, Inc.

Jim Shook has over 35 years of experience involving all aspects of pharmaceutical development including pharmacology, toxicology, pathology, pharmaceutics, pharmacokinetics, clinical pharmacology, biostatistics, data management, SAS programming, clinical research, QA/QC, medical affairs, regulatory affairs and manufacturing. During his career, he has managed and assisted in the preparation of 28 NDAs and 2 PLAs (now BLAs). Among his last 14 submissions, he had the overall project management responsibility for 7, and the total responsibility for preparation, submission and approval for 5. Prior to establishing Jim Shook Research, Inc. specializing product development and regulatory affairs support to the biotech and pharmaceutical companies worldwide, he was the Executive Vice President and Chief Development Officer at Quark Biotech, Inc. Prior to Quark Biotech, he held executive positions at numerous companies including Athersys, Salix Pharmaceuticals, Fujisawa USA, Genentech and Abbott Laboratories.

Philip Morgan, Ph.D. , Former Head of Molecular Pharmacology, GlaxoSmithKline

Phil Morgan has over 25 years of experienced in pharmacology with extensive knowledge of all phases of drug development from discovery through commercialization. Therapeutic areas of expertise include neurology, psychiatry, metabolic disorders, inflammation, incontinence, osteoporosis and osteoarthritis. He has extensive record of successful (IND/NDA) interactions with the FDA and other regulatory agencies. He is also a founder of several biotechnology companies and serves as an advisor to several pharmaceutical companies and venture capital companies.